Fulgent Genetics Stock Price, News & Analysis (NASDAQ:FLGT)

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics Inc (NASDAQ:FLGT) posted its quarterly earnings results on Monday, August, 5th. The company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.06. The business had revenue of $8.42 million for the quarter, compared to the consensus estimate of $6.42 million. Fulgent Genetics had a negative return on equity of 4.71% and a negative net margin of 12.38%. View Fulgent Genetics' Earnings History.

Fulgent Genetics is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Fulgent Genetics.

Fulgent Genetics will be holding an earnings conference call on Monday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

2 brokerages have issued 1-year price objectives for Fulgent Genetics' shares. Their predictions range from $9.50 to $9.50. On average, they anticipate Fulgent Genetics' stock price to reach $9.50 in the next year. This suggests that the stock has a possible downside of 17.5%. View Analyst Price Targets for Fulgent Genetics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Fulgent Genetics.

Media stories about FLGT stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fulgent Genetics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Fulgent Genetics.

Fulgent Genetics saw a decrease in short interest during the month of September. As of September 15th, there was short interest totalling 102,400 shares, a decrease of 5.2% from the August 15th total of 108,000 shares. Based on an average trading volume of 70,100 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.6% of the company's shares are short sold. View Fulgent Genetics' Current Options Chain.

Some companies that are related to Fulgent Genetics include RadNet (RDNT), Personalis (PSNL), Castle Biosciences (CSTL), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS), OpGen (OPGN) and Aeon Global Health (AGHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include Crispr Therapeutics (CRSP), Zynerba Pharmaceuticals (ZYNE), Baidu (BIDU), Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Intellia Therapeutics (NTLA), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP), DexCom (DXCM) and Fate Therapeutics (FATE).

(FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FLGT stock can currently be purchased for approximately $11.51.

Fulgent Genetics has a market capitalization of $212.82 million and generates $21.36 million in revenue each year. The company earns $-5,610,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe.View Additional Information About Fulgent Genetics.

The official website for Fulgent Genetics is http://www.fulgentgenetics.com/.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE SUITE 205, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]